HK1141008A1 - Purinyl derivatives and their use as potassium channel modulators - Google Patents

Purinyl derivatives and their use as potassium channel modulators

Info

Publication number
HK1141008A1
HK1141008A1 HK10107002.9A HK10107002A HK1141008A1 HK 1141008 A1 HK1141008 A1 HK 1141008A1 HK 10107002 A HK10107002 A HK 10107002A HK 1141008 A1 HK1141008 A1 HK 1141008A1
Authority
HK
Hong Kong
Prior art keywords
potassium channel
channel modulators
purinyl derivatives
purinyl
derivatives
Prior art date
Application number
HK10107002.9A
Other languages
English (en)
Chinese (zh)
Inventor
‧埃裡克森
‧瑟倫森
‧霍高
‧彼得斯
‧約翰森
‧克裡斯托弗森
Original Assignee
有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 有限責任公司 filed Critical 有限責任公司
Publication of HK1141008A1 publication Critical patent/HK1141008A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK10107002.9A 2007-03-28 2010-07-20 Purinyl derivatives and their use as potassium channel modulators HK1141008A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90850307P 2007-03-28 2007-03-28
DKPA200700482 2007-03-28
PCT/EP2008/053648 WO2008116909A1 (en) 2007-03-28 2008-03-27 Purinyl derivatives and their use as potassium channel modulators

Publications (1)

Publication Number Publication Date
HK1141008A1 true HK1141008A1 (en) 2010-10-29

Family

ID=39473604

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107002.9A HK1141008A1 (en) 2007-03-28 2010-07-20 Purinyl derivatives and their use as potassium channel modulators

Country Status (8)

Country Link
US (4) US20100130516A1 (xx)
EP (5) EP2132208A1 (xx)
AU (1) AU2008231695B2 (xx)
CA (1) CA2682019C (xx)
HK (1) HK1141008A1 (xx)
IL (1) IL200501A0 (xx)
MX (1) MX2009010122A (xx)
WO (5) WO2008116909A1 (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
JP2010517970A (ja) * 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
EP2402341B1 (en) * 2007-03-28 2017-10-25 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
WO2008116909A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
WO2009146406A1 (en) 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CN102177154A (zh) * 2008-09-02 2011-09-07 神经研究公司 吡唑基-嘧啶衍生物及其作为钾通道调节剂的应用
WO2010034707A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2010112486A1 (en) 2009-04-01 2010-10-07 Neurosearch A/S SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS
US8685987B2 (en) 2009-04-01 2014-04-01 Ataxion, Inc. Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators
US20120184517A1 (en) * 2009-04-30 2012-07-19 Steven Marx Treatment of diseases with altered smooth muscle contractility
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
JP5555378B2 (ja) 2010-07-14 2014-07-23 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋｐ１１０デルタに選択的なプリン化合物とその使用の方法
SG190890A1 (en) 2010-12-16 2013-07-31 Hoffmann La Roche Tricyclic pi3k inhibitor compounds and methods of use
WO2012142029A2 (en) * 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
CN102351716B (zh) * 2011-08-17 2013-11-06 中国石油化工股份有限公司 一种降低甲酰苯胺法制备对氨基二苯胺塔设备腐蚀的方法
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2885290B1 (en) 2012-06-26 2017-10-18 Saniona A/S A phenyl triazole derivative and its use for modulating the gabaa receptor complex
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
WO2015005491A1 (ja) * 2013-07-12 2015-01-15 国立大学法人京都大学 疾病の発症又は進行の一因となる異常スプライシングを抑制できる物質のスクリーニング方法
CA2969587A1 (en) 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
SI3303330T1 (sl) 2015-06-03 2019-08-30 Bristol-Myers Squibb Company Agonisti 4-hidroksi-3-(heteroaril)piridin-2-on apj za uporabo pri zdravljenju kardiovaskularnih motenj
EP3341372A1 (en) * 2015-08-25 2018-07-04 Bristol-Myers Squibb Company Tgf beta receptor antagonists
AU2017275657B2 (en) * 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
WO2018075937A1 (en) 2016-10-21 2018-04-26 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
RS62899B1 (sr) 2017-01-23 2022-03-31 Cadent Therapeutics Inc Modulatori kalijumovih kanala
CA3116339A1 (en) 2018-10-22 2020-04-30 Cadent Therapeutics, Inc. Crystalline forms of potassium channel modulators
CN116178374B (zh) * 2023-01-13 2024-10-08 河北医科大学 小电导钙激活钾离子通道激动剂及其合成和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4004066B2 (ja) * 1995-11-01 2007-11-07 ノバルティス アクチエンゲゼルシャフト プリン誘導体およびその製法
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE19834044A1 (de) * 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
JP2003531111A (ja) * 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
US6420384B2 (en) * 1999-12-17 2002-07-16 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
IL150060A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel purines
IL150061A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
EP1399446B1 (en) 2001-06-27 2005-08-03 Cyclacel Limited 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders
US20030078232A1 (en) * 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
US7262176B2 (en) * 2001-08-08 2007-08-28 Cv Therapeutics, Inc. Adenosine A3 receptor agonists
US20060009642A1 (en) * 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
JP2005512972A (ja) * 2001-10-12 2005-05-12 アイアールエム エルエルシー キナーゼ阻害剤足場およびそれらの調製方法
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
JP2006501200A (ja) * 2002-07-23 2006-01-12 スミスクライン ビーチャム コーポレーション キナーゼインヒビターとしてのピラゾロピリミジン
US20030139427A1 (en) * 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) * 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
AU2004264419B2 (en) * 2003-08-15 2009-01-15 Irm Llc 6-substituted anilino purines as RTK inhibitors
WO2005069865A2 (en) * 2004-01-13 2005-08-04 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005080377A1 (ja) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha TGFβ阻害活性を有する化合物およびそれを含んでなる医薬組成物
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
FR2876583B1 (fr) * 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
JP4966958B2 (ja) * 2005-03-14 2012-07-04 ノイロサーチ アクティーゼルスカブ カリウムチャネル調節剤及び医療における使用
GB0505219D0 (en) 2005-03-14 2005-04-20 Novartis Ag Organic compounds
US20090036475A1 (en) * 2005-03-22 2009-02-05 Neurosearch A/S Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2008534472A (ja) 2005-03-22 2008-08-28 ノイロサーチ アクティーゼルスカブ カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
US7514417B2 (en) * 2005-05-19 2009-04-07 Cv Therapeutics, Inc. A1 adenosine receptor agonists
US20090306102A1 (en) * 2005-12-20 2009-12-10 Eriksen Birgitte L 2-pyridin-2-yl-quinazoline derivatives as potassium channel modulating agents for the treatment of respiratory diseases
TW200745847A (en) * 2005-12-23 2007-12-16 Koninkl Philips Electronics Nv Apparatus and method for dynamic cache management
EP2066655A2 (en) * 2006-09-07 2009-06-10 Neurosearch A/S Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents
AU2007304195A1 (en) 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101622001A (zh) * 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
JP2010517970A (ja) * 2007-02-02 2010-05-27 ノイロサーチ アクティーゼルスカブ ピリジニル−ピラゾール誘導体及びカリウムチャネル調節剤としてのそれらの使用
WO2008116909A1 (en) * 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
EP2402341B1 (en) * 2007-03-28 2017-10-25 Saniona A/S Purinyl derivatives and their use as potassium channel modulators
US20100197914A1 (en) * 2007-10-17 2010-08-05 Robin Alec Fairhurst Purine Derivatives as Adenosine Al Receptor Ligands
WO2010034707A1 (en) * 2008-09-26 2010-04-01 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
US20110237607A1 (en) * 2008-09-26 2011-09-29 Neurosearch A/S Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas

Also Published As

Publication number Publication date
US9340544B2 (en) 2016-05-17
EP2142546A1 (en) 2010-01-13
WO2008116914A1 (en) 2008-10-02
US8362024B2 (en) 2013-01-29
US20100130516A1 (en) 2010-05-27
AU2008231695A1 (en) 2008-10-02
AU2008231695B2 (en) 2013-03-28
MX2009010122A (es) 2009-10-19
EP2142547A1 (en) 2010-01-13
EP2142545A1 (en) 2010-01-13
CA2682019C (en) 2016-08-09
US20130109704A1 (en) 2013-05-02
EP2142546B1 (en) 2017-06-07
US20100120797A1 (en) 2010-05-13
WO2008116909A1 (en) 2008-10-02
EP2144911A2 (en) 2010-01-20
WO2008116912A2 (en) 2008-10-02
EP2132208A1 (en) 2009-12-16
WO2008116912A3 (en) 2009-02-05
CA2682019A1 (en) 2008-10-02
WO2008116911A1 (en) 2008-10-02
IL200501A0 (en) 2010-04-29
US20100152210A1 (en) 2010-06-17
WO2008116910A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
HK1141008A1 (en) Purinyl derivatives and their use as potassium channel modulators
ZA200905796B (en) Purinyl derivatives and their use as potassium channel modulators
AP2516A (en) 2-Pyridine carboxamide derivatives as sodium channel modulators
ZA201000436B (en) Novel esterases and their use
EP2178373A4 (en) HETEROCYCLES AS COLD CHANNEL MODULATORS
GB0701426D0 (en) Compounds and their use
GB0700580D0 (en) Use
HK1147968A1 (en) Biphenylcarboxamide derivatives as hedgehog pathway modulators
GB0723794D0 (en) Potassium ion channel modulators and uses thereof
LT2194783T (lt) Apoptozės moduliatorių kompozicijos ir būdai
GB0712503D0 (en) Use
PL2129680T3 (pl) Łączone kompozycje cząsteczek antysensownych o strukturze spinki do włosów oraz sposoby modulacji ekspresji
IL208771A0 (en) Iminopyridine derivatives and use thereof
SI2170861T1 (sl) Derivati 4-(n-azacikloalkil) anilidov kot kalijevi kanalski modulatorji
EP2174629A4 (en) BUFFER
EP2170874A4 (en) NEW COMPOUNDS AND THEIR USE
PT2027842E (pt) Produto absorvente
GB0724246D0 (en) Noval use
ZA201000357B (en) 2-Azetidinemethaneamines and 2-pyrrolidinemethaneamines as Taar-Ligands
EP2310369A4 (en) BENZYL OXYANILID DERIVATIVES SUITABLE AS SODIUM CHANNEL MODULATORS
GB0701096D0 (en) Use
GB2454741B (en) Wristband
GB0711036D0 (en) Composition and their use
GB0722678D0 (en) Compounds and their use II
GB0725186D0 (en) Learners mate